A recent study revealed that concomitant administration of a7 subtype of nicotinic acetylcholine receptor (a7-nAChR) agonist and Sig-1R agonist exert neuroprotective and anti-inflammatory effects in a 6-OHDA model of PD (Vetel et al., 2021). Here, SIGMAR1 is linked to Parkinson disease.